Mesoblast Announces Pricing Of Public Offering On Nasdaq
13 nov. 2015 08h38 HE
|
Mesoblast
NEW YORK and MELBOURNE, Australia, Nov. 13, 2015 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ:MESO) (ASX:MSB), a world leader in the development of innovative cell-based medicines, today announced...
Mesoblast Chairman's Address to 2015 Annual General Meeting
22 oct. 2015 02h00 HE
|
Mesoblast
NEW YORK, Oct. 22, 2015 (GLOBE NEWSWIRE) -- Thank you for attending the Mesoblast 2015 Annual General Meeting.
This has been another exciting and productive year in the history of our...
Type 2 Diabetes Trial Results Published In Diabetes Care
22 juil. 2015 19h17 HE
|
Mesoblast
NEW YORK and MELBOURNE, Australia, July 22, 2015 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB; USOTC: MBLTY) today announced that results of the Phase 2 trial of its intravenously-delivered...
Postive Trial Results Of Mesoblast Cell Therapy In Patients With Diabetes And Advanced Chronic Kidney Disease
08 juin 2015 21h12 HE
|
Mesoblast
NEW YORK and MELBOURNE, Australia, June 8, 2015 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB; USOTC: MBLTY) today announced that results from the Company's Phase 2 trial in patients with diabetic...
Diabetic Nephropathy Trial Results Selected For Late-Breaking Presentation At American Diabetes Association Annual Meeting
18 mai 2015 05h39 HE
|
Mesoblast
NEW YORK and MELBOURNE, Australia, May 18, 2015 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB; USOTC: MBLTY) today announced that Phase 2 trial results of its lead product candidate for the treatment...
Mesoblast Unveils Path to Bring Its Key Products to Market
25 août 2014 20h27 HE
|
Mesoblast
NEW YORK and MELBOURNE, Australia, Aug. 25, 2014 (GLOBE NEWSWIRE) -- Regenerative medicine company Mesoblast Limited (ASX: MSB; USOTC: MBLTY) today reported 2014 financial results and unveiled its...
SCRIP Award to Mesoblast Recognizes Strategic Importance of '2013 Financing Deal of the Year'
22 nov. 2013 06h00 HE
|
Mesoblast
NEW YORK and MELBOURNE, Australia, Nov. 22, 2013 (GLOBE NEWSWIRE) -- Regenerative medicine company Mesoblast Limited (ASX: MSB; OTC ADR: MBLTY) announced that it was today awarded the 'Financing Deal...
MESOBLAST UPDATES MARKET ON REGISTRATION PLANS FOR GVHD CELL PRODUCT IN JAPAN
28 oct. 2013 01h11 HE
|
Mesoblast
MELBOURNE, Australia and NEW YORK, Oct. 28, 2013 (GLOBE NEWSWIRE) -- Regenerative medicine company Mesoblast Limited (ASX:MSB) (USOTC:MBLTY) today updated the market on product registration plans in...
Mesoblast Completes A$170m Private Placement
13 mars 2013 23h08 HE
|
Mesoblast
MELBOURNE, Australia, March 13, 2013 (GLOBE NEWSWIRE) -- Regenerative medicine company Mesoblast Limited (ASX:MSB) (USOTC:MBLTY) today announced that it has completed a private placement of its...